Indian Firm Seeks To Prove New Drugs Can Be Developed Cheaply
This article was originally published in PharmAsia News
An investment company in India has poured more than $61 million into five companies as part of an effort to prove drug development can be done more cheaply than is the practice today. Nadathur Holdings and Investments says it seeks to disprove the assumption new-drug development requires as much as $1 billion. Nadathur has created Lifespring Ventures as a subsidiary, now owner itself of five start-up firms in the drug-discovery process. The firms operate as stand-alone companies trying to find treatments focusing on metabolic syndrome connected to heart, stroke and diabetes conditions. (Click here for more
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?